If you have already registered, please check your email for the webinar link.

Event Overview

Immune responses are controlled by an exquisite system of stimulatory and inhibitory checkpoints. Cancer cells often find a way to co-opt these checkpoints to avoid being attacked by the immune system. There is growing interest in blocking inhibitory innate immune checkpoints such as the “don’t eat me” signal, CD47, which is commonly overexpressed on cancer cells, and the TAM receptor family of tyrosine kinases. Also, small molecule agonists against STING—a protein that ramps up production of interferons and cytokines—are major targets on the radar for therapeutic development, as well as molecules that target Toll-like Receptors (TLRs) and RIG-I-like Receptors (RLRs). Join us for a discussion about first-in-class STING agonists and innate immune checkpoints in cancer.

Topics to be Covered
  • Immune Oncology beyond PD1: preclinical and first clinical data using ADU-S100, a first-in-class STING agonist
  • Mechanism of an immune-modulating biologic for late-stage cancer
  • The CD47-SIRPα innate immune checkpoint in cancer
Tuesday, March 26, 2019
2:30 - 4:00 PM Eastern Time


EvanAlsas Adura.png
Andrea van Elsas, PhD
Chief Scientific Officer
Aduro Biotech, Inc.

Jeremy Graff.png
Jeremy R Graff, PhD
President and Chief Scientific Officer
Biothera Pharmaceuticals, Inc.

Timo Berg.png
Timo K. van den Berg, PhD
Professor (Immunotherapy), Depts. Molecular Cell Biology and Immunology
VU Medical Center
Head, Dept. Blood Cell Research, Sanquin Research
Academic Medical Center Amsterdam

cisbio logo.png

Register Now

Keeping Cancer in Check: Innate Immunity and Checkpoint Inhibitors

You must have Javascript and Cookies enabled to access this webcast.

Information you provide will be held in confidence and will be shared with the sponsoring vendor(s) of this webinar. We may use the information to contact you about your account and to let you know about related programs and products; you may opt-out at any time. This allows The Scientist to keep these webinars free of charge for our readers.